1. Home
  2. ULBI vs TLSI Comparison

ULBI vs TLSI Comparison

Compare ULBI & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ultralife Corporation

ULBI

Ultralife Corporation

HOLD

Current Price

$5.60

Market Cap

102.1M

Sector

Miscellaneous

ML Signal

HOLD

Logo TriSalus Life Sciences Inc.

TLSI

TriSalus Life Sciences Inc.

N/A

Current Price

$4.67

Market Cap

270.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ULBI
TLSI
Founded
1990
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Medical Specialities
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
102.1M
270.2M
IPO Year
1995
2020

Fundamental Metrics

Financial Performance
Metric
ULBI
TLSI
Price
$5.60
$4.67
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$7.00
AVG Volume (30 Days)
33.7K
107.2K
Earning Date
05-12-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
13.00
N/A
Revenue
$191,159,000.00
$45,151,000.00
Revenue This Year
$20.00
$35.45
Revenue Next Year
N/A
$37.58
P/E Ratio
$0.43
N/A
Revenue Growth
16.24
53.41
52 Week Low
$4.90
$2.20
52 Week High
$8.25
$7.95

Technical Indicators

Market Signals
Indicator
ULBI
TLSI
Relative Strength Index (RSI) 32.20 42.35
Support Level $5.54 $4.21
Resistance Level $5.66 $4.82
Average True Range (ATR) 0.26 0.29
MACD -0.14 -0.08
Stochastic Oscillator 12.57 4.23

Price Performance

Historical Comparison
ULBI
TLSI

About ULBI Ultralife Corporation

Ultralife Corp provides products and services ranging from power solutions to communications and electronics systems to customers across the globe in the government and defense, medical, safety and security, energy, and industrial sectors. The company also designs, manufactures, installs, and maintains power and communications systems including rechargeable and non-rechargeable batteries, charging systems, communications and electronics systems and accessories, and custom-engineered systems. The company's segments include Battery and Energy Products, and Communications Systems. It generates maximum revenue from the Battery and Energy Products segment, and from the U.S. The Battery & Energy Products segment includes Lithium 9-volt, cylindrical, and various other non-rechargeable batteries.

About TLSI TriSalus Life Sciences Inc.

TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.

Share on Social Networks: